Genelux (GNLX) to Release Earnings on Friday

Genelux (NASDAQ:GNLX - Get Free Report) will likely be announcing its Q4 2024 earnings results before the market opens on Friday, March 28th. Analysts expect Genelux to post earnings of ($0.17) per share for the quarter.

Genelux (NASDAQ:GNLX - Get Free Report) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). On average, analysts expect Genelux to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Genelux Stock Performance

Shares of Genelux stock traded down $0.38 during midday trading on Monday, reaching $2.70. 247,294 shares of the company's stock traded hands, compared to its average volume of 206,074. The stock has a 50 day moving average of $4.06 and a 200-day moving average of $3.10. Genelux has a 12 month low of $1.60 and a 12 month high of $6.50. The company has a market cap of $93.77 million, a PE ratio of -2.84 and a beta of -1.41.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Genelux in a research report on Monday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $18.25.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.